Literature DB >> 19498429

Multiple sclerosis: Hematopoietic stem cell transplantation: hope and hype.

Martin Stangel1.   

Abstract

A trial of autologous hematopoietic stem cell transplantation to treat multiple sclerosis has yielded promising results, generating considerable interest within both the clinical literature and the mainstream press.the findings should, however, be interpreted with some caution, and larger, randomized trials will be required to establish the true efficacy of the approach.

Entities:  

Mesh：

Year:  2009        PMID： 19498429     DOI： 10.1038/nrneurol.2009.63

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


  10 in total

1.  The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study.

Authors:  L Roccatagliata; Ma Rocca; P Valsasina; L Bonzano; Mp Sormani; R Saccardi; Gl Mancardi; M Filippi
Journal:  Mult Scler       Date:  2007-04-27       Impact factor: 6.312

Review 2.  Autologous and allogeneic hematopoietic stem cell transplantation for Multiple Sclerosis: perspective on mechanisms of action.

Authors:  Bart Van Wijmeersch; Ben Sprangers; Bénédicte Dubois; Mark Waer; An D Billiau
Journal:  J Neuroimmunol       Date:  2008-06-09       Impact factor: 3.478

3.  Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis.

Authors:  J T Chen; D L Collins; H L Atkins; M S Freedman; A Galal; D L Arnold
Journal:  Neurology       Date:  2006-06-27       Impact factor: 9.910

4.  Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis.

Authors:  Imke Metz; Claudia F Lucchinetti; Harry Openshaw; Antonio Garcia-Merino; Hans Lassmann; Marc S Freedman; Harold L Atkins; Biagio Azzarelli; Oldrich J Kolar; Wolfgang Brück
Journal:  Brain       Date:  2007-02-09       Impact factor: 13.501

Review 5.  Autologous haematopoietic stem-cell transplantation in multiple sclerosis.

Authors:  Gianluigi Mancardi; Riccardo Saccardi
Journal:  Lancet Neurol       Date:  2008-07       Impact factor: 44.182

6.  Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.

Authors:  Richard K Burt; Yvonne Loh; Bruce Cohen; Dusan Stefoski; Dusan Stefosky; Roumen Balabanov; George Katsamakis; Yu Oyama; Eric J Russell; Jessica Stern; Paolo Muraro; John Rose; Alessandro Testori; Jurate Bucha; Borko Jovanovic; Francesca Milanetti; Jan Storek; Julio C Voltarelli; William H Burns
Journal:  Lancet Neurol       Date:  2009-01-29       Impact factor: 44.182

7.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Authors:  Stephen L Hauser; Emmanuelle Waubant; Douglas L Arnold; Timothy Vollmer; Jack Antel; Robert J Fox; Amit Bar-Or; Michael Panzara; Neena Sarkar; Sunil Agarwal; Annette Langer-Gould; Craig H Smith
Journal:  N Engl J Med       Date:  2008-02-14       Impact factor: 91.245

8.  The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

Authors:  Alasdair J Coles; Amanda Cox; Emmanuelle Le Page; Joanne Jones; S Anand Trip; Jackie Deans; Shaun Seaman; David H Miller; Geoff Hale; Herman Waldmann; D Alastair Compston
Journal:  J Neurol       Date:  2005-07-27       Impact factor: 4.849

9.  Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients.

Authors:  Paolo A Muraro; Daniel C Douek; Amy Packer; Katherine Chung; Francisco J Guenaga; Riccardo Cassiani-Ingoni; Catherine Campbell; Sarfraz Memon; James W Nagle; Frances T Hakim; Ronald E Gress; Henry F McFarland; Richard K Burt; Roland Martin
Journal:  J Exp Med       Date:  2005-02-28       Impact factor: 14.307

10.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Authors:  Alasdair J Coles; D Alastair S Compston; Krzysztof W Selmaj; Stephen L Lake; Susan Moran; David H Margolin; Kim Norris; P K Tandon
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245
  10 in total
  2 in total

Review 1.  Immune mechanisms underlying the beneficial effects of autologous hematopoietic stem cell transplantation in multiple sclerosis.

Authors:  David Gosselin; Serge Rivest
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

Review 2.  Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies.

Authors:  Marcelo C Pasquini; Linda M Griffith; Douglas L Arnold; Harold L Atkins; James D Bowen; Jacqueline T Chen; Mark S Freedman; George H Kraft; Gian Luigi Mancardi; Roland Martin; Paolo A Muraro; Richard A Nash; Michael K Racke; Jan Storek; Riccardo Saccardi
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-18       Impact factor: 5.742
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.